PURPOSE: We aimed to describe disease-free survival (DFS) and overall survival (OS) in men with localized or locally advanced prostate cancer receiving immediate hormone therapy as adjunct to radiation therapy, adjunct to radical prostatectomy, or stand-alone therapy. MATERIALS AND METHODS: A systematic literature search of MEDLINE, EMBASE, CancerLit, the Cochrane Library, and Current Contents (from 1986 to September 2006) yielded 35 high-quality clinical trials (n = 11,105 patients) which formed the evidence base. Selected studies were required to address early hormone therapy in nonmetastatic prostate cancer only. Data on DFS and OS were extracted from individual trials, summarized statistically, and displayed in graphic form. RESULTS: Survival probabilities were extracted from 16 trials (n = 5,987 patients) addressing hormone therapy as an adjunct to radiation therapy, 11 trials (n = 1,885 patients) investigating hormone therapy as an adjunct to prostatectomy, and 10 trials (n = 3,233 patients) evaluating hormone therapy alone. In men receiving hormones and radiation, estimated 5-year DFS and OS were 52% and 82%, whereas median DFS and OS were 5.4 years and more than 7 years, respectively. In men receiving hormones and surgery, 5-year DFS and OS were 64% and 90%, whereas median DFS and OS were more than 6 years and more than 7 years, respectively. In men receiving hormones alone, 5-year DFS and OS were 57% and 70%, whereas median DFS and OS were 6.0 years and more than 7 years, respectively. CONCLUSION: This systematic review provides a new baseline for expected DFS and OS in patients treated with hormone therapy for nonmetastatic prostate cancer. Survival in these men may be longer than estimated previously.
PURPOSE: We aimed to describe disease-free survival (DFS) and overall survival (OS) in men with localized or locally advanced prostate cancer receiving immediate hormone therapy as adjunct to radiation therapy, adjunct to radical prostatectomy, or stand-alone therapy. MATERIALS AND METHODS: A systematic literature search of MEDLINE, EMBASE, CancerLit, the Cochrane Library, and Current Contents (from 1986 to September 2006) yielded 35 high-quality clinical trials (n = 11,105 patients) which formed the evidence base. Selected studies were required to address early hormone therapy in nonmetastatic prostate cancer only. Data on DFS and OS were extracted from individual trials, summarized statistically, and displayed in graphic form. RESULTS: Survival probabilities were extracted from 16 trials (n = 5,987 patients) addressing hormone therapy as an adjunct to radiation therapy, 11 trials (n = 1,885 patients) investigating hormone therapy as an adjunct to prostatectomy, and 10 trials (n = 3,233 patients) evaluating hormone therapy alone. In men receiving hormones and radiation, estimated 5-year DFS and OS were 52% and 82%, whereas median DFS and OS were 5.4 years and more than 7 years, respectively. In men receiving hormones and surgery, 5-year DFS and OS were 64% and 90%, whereas median DFS and OS were more than 6 years and more than 7 years, respectively. In men receiving hormones alone, 5-year DFS and OS were 57% and 70%, whereas median DFS and OS were 6.0 years and more than 7 years, respectively. CONCLUSION: This systematic review provides a new baseline for expected DFS and OS in patients treated with hormone therapy for nonmetastatic prostate cancer. Survival in these men may be longer than estimated previously.
Authors: Anthony V D'Amico; Marian Loffredo; Andrew A Renshaw; Brittany Loffredo; Ming-Hui Chen Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: C J Tyrrell; J E Altwein; F Klippel; C Jurincic-Winkler; E Varenhorst; G Lunglmayr; F Boccardo; I M Holdaway; J M Haefliger; J P Jordaan Journal: Eur Urol Date: 2000-02 Impact factor: 20.096
Authors: Chris J Tyrrell; Peter Iversen; Teuvo Tammela; John Anderson; Thomas Björk; Amir V Kaisary; Thomas Morris Journal: BJU Int Date: 2006-06-08 Impact factor: 5.588
Authors: P Iversen; C J Tyrrell; A V Kaisary; J B Anderson; L Baert; T Tammela; M Chamberlain; K Carroll; K Gotting-Smith; G R Blackledge Journal: Urology Date: 1998-03 Impact factor: 2.649
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: M A Eisenberger; B A Blumenstein; E D Crawford; G Miller; D G McLeod; P J Loehrer; G Wilding; K Sears; D J Culkin; I M Thompson; A J Bueschen; B A Lowe Journal: N Engl J Med Date: 1998-10-08 Impact factor: 91.245
Authors: M J Zelefsky; S A Leibel; P B Gaudin; G J Kutcher; N E Fleshner; E S Venkatramen; V E Reuter; W R Fair; C C Ling; Z Fuks Journal: Int J Radiat Oncol Biol Phys Date: 1998-06-01 Impact factor: 7.038
Authors: Jamie A Johansen; Sandra M Troxell-Smith; Zhigang Yu; Kaiguo Mo; D Ashley Monks; Andrew P Lieberman; S Marc Breedlove; Cynthia L Jordan Journal: Neurodegener Dis Date: 2010-08-04 Impact factor: 2.977
Authors: Simon M Collin; Richard M Martin; Chris Metcalfe; David Gunnell; Peter C Albertsen; David Neal; Freddie Hamdy; Peter Stephens; J Athene Lane; Rollo Moore; Jenny Donovan Journal: Lancet Oncol Date: 2008-04-16 Impact factor: 41.316